Total Company Value: kalvista.com (KALV)
KalVista Pharmaceuticals (KALV) specializes in developing immunological agents while adhering to the principles of green chemistry and sustainable water management. This chart reflects an Enterprise Value of 1436.76. The company leverages its research centers in the UK and US, outsourcing the production of edema medications to third-party contractors. The primary growth driver will be the upcoming results of final trials for its hereditary angioedema therapy.
KalVista Pharmaceuticals (KALV) - metric breakdowns and financial figures
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- business book valuation details:
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio KalVista Pharmaceuticals|KALV - Long-Term Debt to Capital|Short-Term Debt to Capital kalvista.com|KALV - Company Debts|Debt to Net Assets Ratio KalVista Pharmaceuticals|KALV - Company Long-Term Debt|Company Current Liabilities KalVista Pharmaceuticals|Quick Ratio kalvista.com
- net income and valuation multiples indicators:
Analysis of all company metrics:KalVista Pharma
The diversification of orphan drug warehouses at KalVista Pharmaceuticals (KALV) ensures stable margins and operational resilience. These factors directly impact the calculation model that combines the company's market capitalization with its net debt. This metric determines the real business value for a potential buyer, accounting for all liabilities and liquid assets. The investor sees the actual enterprise value net of cash. By analyzing the enterprise value trend, one can assess the balance sheet recovery in advance.
Competitors of KalVista Pharmaceuticals (KALV)
Enterprise Value argenx N.V. ARGX|BNTX - Total Company Value|ABVX: Total Company Value|ADMA (ADMA Biologics) - Real Price to Acquire Entire Company|PTGX (protagonist-inc.com) - Total Company Value|Total Company Value Immunovant|Kiniksa Pharmaceuticals, Ltd. - Full Business Value|Enterprise Value GRFS|ADPT (Adaptive Biotechnologies Inc.) - Value Adjusted for Debt and Cash|Enterprise Value CLDX (Celldex Therapeutics)|Enterprise Value auriniapharma.com AUPH|BCRX - Total Company Value|Value Adjusted for Debt and Cash VERA (Vera Therapeutics Inc)|Dianthus Pharma (DNTH) - Total Company Value|Real Price to Acquire Entire Company Pharvaris Pharma|ABCL (AbCellera Biologics Inc) - Enterprise Value|Enterprise Value tourmalinebio.com|Real Price to Acquire Entire Company PGEN (Precigen)|PHAR (Pharming Group NV) - Value Adjusted for Debt and Cash|Enterprise Value NKTR (Nektar)|Company Buyout Price Upstream Pharma (UPB)|ZBIO - Total Company Value|immunome.com (IMNM) - Real Price to Acquire Entire Company|Gossamer Bio (GOSS) - Total Company Value|Real Price to Acquire Entire Company Septerna, Inc.|Real Price to Acquire Entire Company PVLA|Enterprise Value Savara Pharma|Total Company Value Rigel Pharmaceuticals (RIGL)|anaptysbio.com - Business Value|Enterprise Value ATXS (Astria Therapeutics, Inc.)|enGene Holdings Inc (ENGN) - Total Enterprise Value|RAPT - Total Company Value|JBIO - Enterprise Value|ACRS: Enterprise Value|kyvernatx.com (KYTX) - Enterprise Value|Total Company Value Tiziana Life Sciences Ltd|Total Company Value CABA|Real Price to Acquire Entire Company VTYX (Ventyx Bio)|Total Company Value THTX (Theratechnologies, Inc)|Enterprise Value AVTX (Avalo Therapeutics, Inc)|Company Buyout Price eledon.com (ELDN)|AGEN - Total Company Value|Company Buyout Price Climb Bio Inc. CLYM|ZURA (Zura Bio) - Real Price to Acquire Entire Company|ATYR: Aggregate Business Value|ADAG (Adagene Inc) - Enterprise Value|Enterprise Value Ikena Oncology, Inc.|Real Price to Acquire Entire Company STTK (Shattuck Labs, Inc.)|EQ (equilliumbio.com) - Value Adjusted for Debt and Cash|Total Company Value Connect Biopharma Holdings Limited CNTB|IMUX (Immunic Therapeutics) - Full Business Value|Atara Biotherapeutics Inc - Enterprise Value|Value Adjusted for Debt and Cash IFRX (InflaRx N.V.)|XFOR: Enterprise Value|Adicet Bio, Inc. (ACET) - Enterprise Value|Total Company Value Celularity Inc|INMB: Value Adjusted for Debt and Cash|Total Company Value Barinthus Biotherapeutics (BRNS)|Real Price to Acquire Entire Company kezarlifesciences.com KZR|Enterprise Value SABS (SAB Biotherapeutics, Inc.)|Enterprise Value Akari Therapeutics PLC AKTX|Enlivex Therapeutics, Ltd. - Enterprise Value|Q32 Bio Inc. (QTTB) - Real Price to Acquire Entire Company|GOVX: Enterprise Value|Total Enterprise Value edesabiotech.com (EDSA)|Real Price to Acquire Entire Company IBIO|Enterprise Value Carisma Tx|Real Price to Acquire Entire Company XTLB (XTL Biopharmaceuticals, Ltd.)|Aggregate Business Value BOLT|Enterprise Value HCWB (HCW Biologics)|Company Buyout Price Aptevo Therapeutics, Inc. (APVO)|AIM ImmunoTech Inc. - Enterprise Value|Aditxt (ADTX) - Real Price to Acquire Entire Company|GRI: Enterprise Value|XORTX Corp (XRTX) - Enterprise Value|Total Company Value Vyome Holdings Inc|Total Company Value REVB|Total Company Value Indaptus Therapeutics, Inc. (INDP)|Company Buyout Price Scinai Immunotherapeutics Ltd|Total Company Value CalciMedica CALI|Enterprise Value Affimed NV AFMD|Allakos Therapeutics - Enterprise Value|HOOK - Enterprise Value|igmbio.com (IGMS) - Total Company Value|ITOS (iTeos Therapeutics Inc) - Total Company Value|Real Price to Acquire Entire Company OCEA|Total Company Value TCBP|Total Company Value Third Harmonic Bio (THRD)